tbuckley/cabot-search huggingface dataset:
Abstract P265: Trends In Cardiovascular Disease Risk Factors Among Older Adults (65+ Years) In New York City
Authors: Rienna Russo, Yan Li, Simona Kwon, Chau Trinh-Shevrin, Stella S Yi
Journal: Circulation (2020)

Introduction: There was a 19% increase in the older adult population ages 65 and older in New York City (NYC) between 2005 and 2015, which now comprises about 1.13 million people. Cardiovascular disease (CVD) is the leading cause of death among this older adult population. Dietary modification has been linked to improved CVD outcomes in older adults, demonstrating that prevention efforts are still effective in older age. Over the past decade, NYC has led numerous initiatives to improve dietary and physical activity behaviors. Little is known about the impact of these policies on CVD health and behavioral risk factors among older adults. Hypothesis: We anticipate that cardiovascular disease risk factors (fruit and vegetable intake; sugar-sweetened beverage (SSB) intake; exercise; diabetes; cholesterol; and hypertension) will have remained stagnant over an eight year period, from 2009 to 2017, as older adults remain a largely under-reached population. Methods: The New York City Community Health Survey (CHS) is an annual cross-sectional survey among NYC residents. A trend analysis was conducted using data from 2009 to 2017. Adults aged 65 years and older were included in the analysis (n= 20,771). Annual estimates of the percentage of persons with select CVD risk factors were calculated. Linear regression was used to measure changes over time; binary variables were scaled as 0 to 100 to represent percentages. Nonlinearity assessments were conducted and segmented regression models were used when appropriate. All analyses were conducted in SUDAAN v.11.0.3, using appropriate sample weights incorporating the complex survey design. Results: In 2017, over one-quarter (27.3%; 703/2,576) of older adults were diagnosed with diabetes, and almost two-thirds (64.8%; 1,664 /2,568) were diagnosed with hypertension. Only 10.4% (257/2,475) of older adults consumed 5 or more servings of fruits and vegetables and 17.3% (440/2,548) consumed at least one serving of SSB per day. From 2009-2017, there was an increase in the prevalence of diabetes among older adults (Average Percent Change [APC] 0.68; p&lt;0.0001). There were decreases in the percentages of older adults consuming five or more servings of fruits and vegetables (APC -0.30; p=0.007) and one or more SSB across the years (APC -0.38; p=0.010). From 2010-2014, there was a decrease in the prevalence of older adults with high cholesterol (APC -1.06; p=0.047). There were no significant changes in hypertension or exercise rates over time. Conclusion: Decreases in SSB consumption and cholesterol indicate that some prevention efforts may have reached the older adult population. Despite these successes, more older adults suffer from diabetes and hypertension and fewer consume the recommended five servings of fruits and vegetables. In conclusion, more targeted policies and programs are needed to address CVD risks among older adults, as this population continues to grow.
Acute Appendicitis Incidence—Predisposing Factors, From Microbiota to Socioeconomic Status?
Authors: Paulina Salminen
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Overall survival of primary glioblastoma (GBM) patients (pts) receiving carmustine (BCNU) wafers followed by radiation (RT) and concurrent temozolomide (TMZ) plus rotational multi-agent chemotherapy
Authors: J. N. Rich, M. L. Affronti, J. M. Day, J. E. Herndon, J. A. Quinn, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, H. S. Friedman
Journal: Journal of Clinical Oncology (2007)

2070 Background: Treatment of pts with primary GBM using BCNU wafer implantation at initial surgery (Westphal, 2003) as well as the administration of TMZ concurrently and after RT (Stupp, 2005) have each been shown to increase survival. Thus, we hypothesize that the use of the combination of BCNU wafer followed by RT and concurrent (TMZ) plus rotational multi-agent chemotherapy (CCNU, TMZ, CPT-11) will increase survival compared to pts that do not receive BCNU wafers. Methods: Retrospective IRB-approved analysis was conducted on 85 eligible GBM pts who received surgery with (36 pts) and without (49 pts) BCNU wafer insertion followed by RT and concurrent (TMZ) plus adjuvant rotational multi-agent chemotherapy. Survival was estimated within treatment groups using the Kaplan-Meier method. Cox regression was used to evaluate the effect of BCNU wafers on survival after controlling for covariates such as RPA (Recursive Partition Analysis) class, race, and gender. Results: Within the non-BCNU wafer cohort, 39% of patients were younger than 50 and 89% had KPS&gt;70%. Within the BCNU cohort, 31% of patients were younger than 50 and 94% had KPS&gt;70. Overall 1- and 2-year survival for the non-BCNU wafer cohort was 67% (95% CI: 55%, 82%) and 27% (95% CI: 17%, 42%), respectively, with a median survival of 72.7 wks (median follow-up: 123.9; range 14.3–198). Overall 1-year survival for the BCNU wafer cohort was 78% (95% CI: 65%, 93%) with a median survival of 89.6 wks (median follow-up: 118.6; range 26.7–192.1). Given the trends towards significance (p=0.092) between the two groups using a log-rank test, a Cox regression model to control for known prognostic factors was examined: Conclusions: After controlling for the effects due to RPA class, a significant difference in survival is found between treatment groups (p = 0.0325) and patients receiving BCNU wafers have a lower risk of death (HR = 0.548) than patients not receiving BCNU wafers. [Table: see text] No significant financial relationships to disclose.
Diabetes Mellitus as a Strong Predictor for Attenuated Heart Rate Reserve During Exercise in Hypertrophic Cardiomyopathy Patients
Authors: In-Cheol Kim, Jaewon Oh, Jong-Chan Youn, Hyungseop Kim, Geu-Ru Hong, Jong-Min Hwang, Cheol Hyun Lee, Yun-Kyeong Cho, Hyoung-Seob Park, Hyuck-Jun Yoon, Chang-Wook Nam, Seongwook Han, Seung-Ho Hur, Seok-Min Kang
Journal: Metabolism (2020)
Fixing the Parent Trap for Resident Physicians
Authors: Bridget M. Kuehn
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore
Authors: Barnaby Edward Young, Sean Wei Xiang Ong, Shirin Kalimuddin, Jenny G. Low, Seow Yen Tan, Jiashen Loh, Oon-Tek Ng, Kalisvar Marimuthu, Li Wei Ang, Tze Minn Mak, Sok Kiang Lau, Danielle E. Anderson, Kian Sing Chan, Thean Yen Tan, Tong Yong Ng, Lin Cui, Zubaidah Said, Lalitha Kurupatham, Mark I-Cheng Chen, Monica Chan, Shawn Vasoo, Lin-Fa Wang, Boon Huan Tan, Raymond Tzer Pin Lin, Vernon Jian Ming Lee, Yee-Sin Leo, David Chien Lye
Journal: JAMA (2020)

<h3>Importance</h3> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in December 2019 and has spread globally with sustained human-to-human transmission outside China. <h3>Objective</h3> To report the initial experience in Singapore with the epidemiologic investigation of this outbreak, clinical features, and management. <h3>Design, Setting, and Participants</h3> Descriptive case series of the first 18 patients diagnosed with polymerase chain reaction (PCR)–confirmed SARS-CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020; final follow-up date was February 25, 2020. <h3>Exposures</h3> Confirmed SARS-CoV-2 infection. <h3>Main Outcomes and Measures</h3> Clinical, laboratory, and radiologic data were collected, including PCR cycle threshold values from nasopharyngeal swabs and viral shedding in blood, urine, and stool. Clinical course was summarized, including requirement for supplemental oxygen and intensive care and use of empirical treatment with lopinavir-ritonavir. <h3>Results</h3> Among the 18 hospitalized patients with PCR-confirmed SARS-CoV-2 infection (median age, 47 years; 9 [50%] women), clinical presentation was an upper respiratory tract infection in 12 (67%), and viral shedding from the nasopharynx was prolonged for 7 days or longer among 15 (83%). Six individuals (33%) required supplemental oxygen; of these, 2 required intensive care. There were no deaths. Virus was detectable in the stool (4/8 [50%]) and blood (1/12 [8%]) by PCR but not in urine. Five individuals requiring supplemental oxygen were treated with lopinavir-ritonavir. For 3 of the 5 patients, fever resolved and supplemental oxygen requirement was reduced within 3 days, whereas 2 deteriorated with progressive respiratory failure. Four of the 5 patients treated with lopinavir-ritonavir developed nausea, vomiting, and/or diarrhea, and 3 developed abnormal liver function test results. <h3>Conclusions and Relevance</h3> Among the first 18 patients diagnosed with SARS-CoV-2 infection in Singapore, clinical presentation was frequently a mild respiratory tract infection. Some patients required supplemental oxygen and had variable clinical outcomes following treatment with an antiretroviral agent.
Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study
Authors: F. Maindrault-Goebel, G. Lledo, B. Chibaudel, L. Mineur, T. Andre, M. Bennamoun, M. Mabro, P. Artru, C. Louvet, A. de Gramont
Journal: Journal of Clinical Oncology (2007)

4013 Background: The OPTIMOX2 study was designed to evaluate a complete stop of chemotherapy after 6 bimonthly cycles of FOLFOX. Methods: OPTIMOX2 is a large phase II study performed before the availability of bevacizumab. Patients (pts) were randomized between an OPTIMOX1 arm: 6 cycles of FOLFOX7 followed by LV5FU2 until progression then reintroduction of FOLFOX7, and the OPTIMOX2 arm: 6 cycles of FOLFOX7, complete stop of chemotherapy and reintroduction of FOLFOX7 before the tumor progression reached the baseline measures. Results: 202 pts were included between Feb 2004 and Apr 2006. Response rates were (OPTIMOX1/OPTIMOX2): CR+PR 63%/61%. Median PFS were OPTIMOX1/OPTIMOX2) 8.3/6.7 months (p=.04). Median duration of disease control (DDC), addition of PFS of first FOLFOX7 administration plus PFS of FOLFOX reintroduction if no progression at first evaluation, was 10.8m in the OPTIMOX1 arm and 9.0m in the OPTIMOX2 arm, p=.32. Median duration of chemotherapy-free interval (CFI) in the OPTIMOX2 arm was 4.6 months. Patients with poor prognostic factors had a shorter CFI, p=.01. Median overall survival was 24.6m in the OPTIMOX1 arm and 18.9m in the OPTIMOX2 arm, p=.05. Median survivals (OPTIMOX1/OPTIMOX2) were not reached/28.7m in patients with good prognostic and 20.9/14.5m in patients with poor prognostic. Conclusions: Maintenance LV5FU therapy prolongs PFS and OS, especially in patients with poor prognosis. CFI can be recommended only in selected patients without adverse prognostic factors. Our next study, DREAM, is evaluating maintenance therapy with targeted agents alone. No significant financial relationships to disclose.
Metastatic Versus Osteoporotic Vertebral Fractures on MRI: A Blinded, Multicenter, and Multispecialty Observer Agreement Evaluation
Authors: Estanislao Arana, Francisco M. Kovacs, Ana Royuela, Beatriz Asenjo, Fatima Nagib, Sandra Pérez-Aguilera, María Dejoz, Alberto Cabrera-Zubizarreta, Yolanda García-Hidalgo, Ana Estremera, _ _
Journal: Journal of the National Comprehensive Cancer Network (2020)

MRI is assumed to be valid for distinguishing metastatic vertebral fractures (MVFs) from osteoporotic vertebral fractures (OVFs). This study assessed (1) concordance between the image-based diagnosis of MVF versus OVF and the reference (biopsy or follow-up of >6 months), (2) interobserver and intraobserver agreement on key imaging findings and the diagnosis of MVF versus OVF, and (3) whether disclosing a patient's history of cancer leads to variations in diagnosis, concordance, or agreement.This retrospective cohort study included clinical data and imaging from 203 patients with confirmed MVF or OVF provided to 25 clinicians (neurosurgeons, radiologists, orthopedic surgeons, and radiation oncologists). From January 2018 through October 2018, the clinicians interpreted images in conditions as close as possible to routine practice. Each specialist assessed data twice, with a minimum 6-week interval, blinded to assessments made by other clinicians and to their own previous assessments. The kappa statistic was used to assess interobserver and intraobserver agreement on key imaging findings, diagnosis (MVF vs OVF), and concordance with the reference. Subgroup analyses were based on clinicians' specialty, years of experience, and complexity of the hospital where they worked.For diagnosis of MVF versus OVF, interobserver agreement was fair, whereas intraobserver agreement was substantial. Only the latter improved to almost perfect when a patient's history of cancer was disclosed. Interobserver agreement for key imaging findings was fair or moderate, whereas intraobserver agreement on key imaging findings was moderate or substantial. Concordance between the diagnosis of MVF versus OVF and the reference was moderate. Results were similar regardless of clinicians' specialty, experience, and hospital category.When MRI is used to distinguish MVF versus OVF, interobserver agreement and concordance with the reference were moderate. These results cast doubt on the reliability of basing such a diagnosis on MRI in routine practice.
Increased risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers after breast-conserving therapy compared to mastectomy
Authors: R. K. Schmutzler, M. K. Graeser, K. Rhiem, B. Schlehe, W. Hofmann, W. Jonat, I. Schönbuchner, M. Kiechle-Bahat, K. Strunz, C. Engel
Journal: Journal of Clinical Oncology (2007)

1512 Background: BRCA mutation carriers affected by breast cancer face an elevated risk of contralateral breast cancer (clBrCa). We here aimed at estimating the influence of breast conserving therapy (BCT) versus mastectomy (MXT) on the rik of clBrCa. Methods: We conducted a retrospective cohort study in 3810 index patients (pts) collected within the CHBOC. Deleterious BRCA1 or BRCA2 mutations were detected in 921 pts and medical records were obtained from 532 pts (344 BRCA1, 184 BRCA2 mutation carriers, 4 both) of whom 261 (49%) underwent BCT and 271 (51%) MXT. Pts were followed from the initial diagnosis of breast cancer until clBrCa or censored at time of prophylactic contralateral mastectomy, oophorectomy, death, or date of last visit. Median age at first diagnosis was 39.9 years (range 17.5 to 79.0) and median follow up 48.84 months (3413 person years). The hazard ratio (HR) was estimated using multivariate Cox regression analysis adjusting for conduct of radiotherapy, age at first breast cancer, and affected BRCA gene. Results: In the univariate analysis the risk of clBrCa was 12.2% (95% CI 7.6 to 16.8) at 5 years and 24.9% (95% CI 18.0 to 31.9) at 10 years for pts treated with MXT and 25.9% (95% CI 18.8 to 33.1) at 5 years and 45.7% (95% CI 35.0 to 56.5) at 10 years for pts treated with BCT. In the multivariate analysis, the HR was 1.8 for BCT versus MXT (95% CI 1.2 to 2.7). Neither age at diagnosis of the first primary nor BRCA mutation status were significantly predictive. A subgroup analysis comparing BCT plus radiotherapy with MXT minus radiotherapy revealed a HR of 1.6 (95% CI 1.02 to 2.56) for the BCT group. Conclusions: We report for the first time a 1.8-fold increased risk of clBrCa in BRCA mutation carriers undergoing BCT versus MXT. Scattered radiation is the most probable causation. Although results from further studies such as the WECARE study should be awaited, our results provide evidence that recommendations for primary brCa treatment of BRCA mutation carriers must to be reconsidered. No significant financial relationships to disclose.
Incidence and significance of thromboembolic events (TE) in patients with gastrointestinal (GI) and non-GI malignancies on systemic cytotoxic therapy
Authors: T. R. Asmis, M. Templeton, R. Trocola, N. Pincus, J. Randazzo, C. Marinela, D. P. Kelsen, M. A. Shah
Journal: Journal of Clinical Oncology (2007)

9049 Background: Although venous thromboembolic events (TE) are commonly associated with solid tumor malignancies, the precise incidence and significance of TE in cancer patients has not been well established. We previously reported a high incidence of TE in patients with GI malignancies enrolled on clinical studies at Memorial Sloan Kettering (MSKCC) (Asmis, GI ASCO 2007), and now explore the prognostic impact of TE in GI and non-GI malignancies. Methods: All patients above the age of 18 enrolled on prospective, investigator-initiated therapeutic clinical trials at MSKCC from January 1, 2003 to December 31, 2005 were reviewed. Serious adverse event monitoring was recorded prospectively and patients were followed regularly as per their protocol. All patients with Grade 3–4 TE were identified and confirmed at chart review. 100 patients without TE were audited to verify TE status, and 4 patients with TE were identified(sensitivity 96.8%, 95%CI 92.1–99.1%; specificity 100%, 95%CI 96.2–100%). Patients were followed for survival. All records were reviewed for baseline anticoagulation use, prior therapy, and date of cancer diagnosis. Results: 2482 patients with solid tumor malignancies were enrolled from 2003 to 2005: median age 58 (range 18–90), 43% female, 7% baseline anticoagulation, 44% previously untreated. 122 (4.8%, 95%CI 4%- 5.7%) had a TE. TE is associated with decreased median survival in patients with non-GI malignancy (10 months vs. 19.5 months) (p=0.0003), whereas the development of TE was not associated with reduced survival in GI malignancies (16.7 months vs 15.6 months (p=0.45)). Conclusions: In patients with non-GI solid tumors, the development of a venous thromboembolism is significantly associated with poor survival. Understanding why this is the case may provide insight to tumor biology and an opportunity to positively impact patient survival. [Table: see text] No significant financial relationships to disclose.
Abstract P242: Aspirin Awareness and Use for Cardiovascular Disease Prevention in a Community of Color
Authors: Jeremy R Van't Hof, Jeffrey Misialek, Niki C Oldenburg, Milton Eder, Russell V Luepker, Sue Duval
Journal: Circulation (2020)

Background: Cardiovascular disease (CVD) and CVD risk factors are high among people of color. Aspirin (ASA) can reduce CVD risk. Yet little is known about primary prevention ASA use and its determinants among people of color. This study examined associations for ASA-related health beliefs and social norms, CVD risk factors and ASA use among Hispanic/Latino (HL) and African American (AA) adults without CVD history. Methods: In-person surveys were administered to adults ages 45-79 years at health fairs and community events in the Minneapolis-St. Paul metro querying demographics, CVD history, CVD risk factors and ASA use. CVD risk perceptions and ASA-related health beliefs and social norms were evaluated using a 4-point Likert scale. Poisson regression with adjustment for age, sex and risk factors was used to examine associations with ASA use. Surveys were offered in English or Spanish. Results: Of the 583 survey participants with no CVD history, 152 identified as HL and 431 as Non-Hispanic-AA. Compared with AA, the HL sample was younger, mean (SD) age of 53.0 (8.6) years vs 59.3 (9.3) years; 54.6% vs 65.7% were female. Risk factors were common among HL and AA, including diabetes (37.5% and 29.0%), hyperlipidemia (28.3% and 36.7%), hypertension (36.8% and 61.0%) and smoking (13.8% and 21.1%). Twenty-two percent of HL and 34% of AA participants regularly used ASA. When asked questions regarding health beliefs and social norms, HL adults had a high frequency of “Don’t Know” responses compared with AA’s (Figure). Participants with more “Don’t Know” responses were less likely to use ASA—RR of 0.87 (95% CI 0.77-0.99). Conversely, ASA use was positively associated with “Agree” responses (RR 1.40, 95% CI 1.29-1.52) and CVD risk factors (RR 1.43 95% CI 1.28-1.59). Associations did not differ by race/ethnicity (interaction p &gt;0.05). Conclusion: ASA uncertainty is more pronounced among HL adults than AA and is associated with less preventive ASA use. Efforts should be made to improve knowledge regarding the appropriate use of ASA in this population.